Roman Butler Fullerton & Co’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.61M | Buy |
27,189
+3,701
| +16% | +$213K | 0.38% | 69 |
|
|
2026
Q1 | $1.39M | Buy |
23,488
+1,464
| +7% | +$85.3K | 0.38% | 66 |
|
|
2025
Q4 | $1.21M | Buy |
22,024
+7,720
| +54% | +$371K | 0.32% | 82 |
|
|
2025
Q3 | $609K | Buy |
14,304
+25
| +0.2% | +$1.17K | 0.16% | 137 |
|
|
2025
Q2 | $692K | Sell |
14,279
-5,899
| -29% | -$290K | 0.2% | 122 |
|
|
2025
Q1 | $1.01M | Buy |
20,178
+1,482
| +8% | +$86.4K | 0.39% | 62 |
|
|
2024
Q4 | $1.13M | Buy |
18,696
+4,718
| +34% | +$264K | 0.36% | 73 |
|
|
2024
Q3 | $737K | Buy |
13,978
+650
| +5% | +$30.5K | 0.22% | 105 |
|
|
2024
Q2 | $548K | Sell |
13,328
-1,810
| -12% | -$81K | 0.18% | 123 |
|
|
2024
Q1 | $744K | Sell |
15,138
-2,291
| -13% | -$117K | 0.28% | 89 |
|
|
2023
Q4 | $866K | Sell |
17,429
-1,652
| -9% | -$86.7K | 0.34% | 77 |
|
|
2023
Q3 | $1.08M | Hold |
19,081
| – | – | 0.51% | 59 |
|
|
2023
Q2 | $1.18M | Sell |
19,081
-1,915
| -9% | -$128K | 0.54% | 54 |
|
|
2023
Q1 | $1.47M | Buy |
20,996
+762
| +4% | +$53.7K | 0.73% | 33 |
|
|
2022
Q4 | $1.46M | Sell |
20,234
-56
| -0.3% | -$4.22K | 0.76% | 36 |
|
|
2022
Q3 | $1.41M | Buy |
20,290
+96
| +0.5% | +$6.96K | 0.9% | 26 |
|
|
2022
Q2 | $1.53M | Buy |
20,194
+42
| +0.2% | +$3.2K | 0.85% | 29 |
|
|
2022
Q1 | $1.47M | Sell |
20,152
-607
| -3% | -$40.8K | 0.68% | 38 |
|
|
2021
Q4 | $1.29M | Sell |
20,759
-89
| -0.4% | -$5.22K | 0.57% | 55 |
|
|
2021
Q3 | $1.19M | Buy |
20,848
+3,130
| +18% | +$206K | 0.55% | 60 |
|
|
2021
Q2 | $1.18M | Buy |
17,718
+99
| +0.6% | +$6.46K | 0.58% | 56 |
|
|
2021
Q1 | $1.14M | Sell |
17,619
-15
| -0.1% | -$933 | 0.57% | 56 |
|
|
2020
Q4 | $1.09M | Buy |
17,634
+99
| +0.6% | +$6.09K | 0.65% | 51 |
|
|
2020
Q3 | $1.06M | Sell |
17,535
-543
| -3% | -$32.7K | 0.69% | 46 |
|
|
2020
Q2 | $1.06M | Sell |
18,078
-24
| -0.1% | -$1.44K | 0.76% | 42 |
|
|
2020
Q1 | $1.01M | Sell |
18,102
-210
| -1% | -$12.8K | 0.89% | 32 |
|
|
2019
Q4 | $1.18M | Buy |
18,312
+289
| +2% | +$16.6K | 0.78% | 34 |
|
|
2019
Q3 | $914K | Buy |
18,023
+120
| +0.7% | +$5.64K | 0.63% | 50 |
|
|
2019
Q2 | $812K | Sell |
17,903
-127
| -0.7% | -$5.92K | 0.55% | 57 |
|
|
2019
Q1 | $860K | Buy |
18,030
+244
| +1% | +$12.2K | 0.6% | 53 |
|
|
2018
Q4 | $849K | Buy |
+17,786
| New | +$956K | 0.72% | 46 |
|
Other funds holding BMY
Roman Butler Fullerton & Co's BMY Position: Q2 2026 in Review
Roman Butler Fullerton & Co increased its Bristol-Myers Squibb (BMY) stake by 16% in Q2 2026, buying an estimated $213K and bringing the position to 27,189 shares worth $1.61M. The position accounts for 0.38% of the portfolio, ranked #69.
Roman Butler Fullerton & Co first reported a position in BMY in Q4 2018 and has held it in 31 quarters since. 2,529 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Roman Butler Fullerton & Co held 27,189 shares of Bristol-Myers Squibb worth $1.61M as of Q2 2026.
- Roman Butler Fullerton & Co bought 3,701 Bristol-Myers Squibb shares in Q2 2026, an estimated $213K.
- Bristol-Myers Squibb made up 0.38% of Roman Butler Fullerton & Co's portfolio in Q2 2026, its #69 holding.
- Roman Butler Fullerton & Co first reported a position in Bristol-Myers Squibb in Q4 2018 and has held it in 31 quarters since.
- 2,529 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Roman Butler Fullerton & Co's 13F filing for Q2 2026, filed 6 Aug 2026.